— Know what they know.
Not Investment Advice

THC NYSE

Tenet Healthcare Corporation
1W: +1.0% 1M: +3.5% 3M: +2.4% YTD: +34.8% 1Y: +30.0% 3Y: +376.6% 5Y: +327.1%
$261.96
-6.99 (-2.60%)
After Hours: $265.80 (+3.84, +1.47%)
Weekly Expected Move ±2.8%
$253 $261 $268 $276 $284
NYSE · Healthcare · Medical - Care Facilities · Tech Score Buy · Power 60 · $21.7B mcap · 80M float · 1.21% daily turnover · Short 44% of daily vol
Credit Risk of going bust: higher than 58% of companies Debt: 38.0% of company value Bonds: $1.43B held by 520 funds, 120 bp over Treasuries → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $12.34 (down 95%), Tenet Healthcare Corporation would be worth roughly what it owes.
Total debt $13.25B against a stock market value of $21.66B.
Distance to default 4.38 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $6.70B (short-term plus half of long-term), stock volatility 42.1%; Altman Z'' 2.25. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

WEAK EDGE
44.9 / 100
NoneWeakNarrowWide
Primary source: Efficient Scale  ·  ROIC: 19.1%  ·  5Y Avg: 11.1%
Cost Advantage
46
Intangibles
31
Switching Cost
48
Network Effect
40
Scale ★
66
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. THC shows a Weak competitive edge (44.9/100) — limited structural advantages that may face competitive pressure. The primary source of advantage is Efficient Scale. ROIC of 19.1% confirms the company is generating returns well above its cost of capital — a hallmark of durable competitive advantages.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$265
Low
$287
Avg Target
$308
High
Based on 15 analysts since Jul 22, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 26Hold: 6Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$287.88
Analysts8
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-10-16 Guggenheim — $242 $307 +65 +11.6% $275.13
2026-09-22 BMO Capital — Initiated $265 — +1.1% $262.06
2026-08-14 Raymond James — $270 $285 +15 +6.6% $267.27
2026-08-10 Mizuho Securities — $225 $290 +65 +10.6% $262.13
2026-08-03 Wells Fargo Stephen Baxter $231 $281 +50 +10.3% $254.78
2026-07-28 Goldman Sachs Scott Fidel $224 $305 +81 +16.1% $262.63
2026-07-28 Truist Financial David MacDonald $270 $290 +20 +19.2% $243.36
2026-07-28 Robert W. Baird Michael Ha $210 $280 +70 +15.1% $243.36
2026-07-27 Stephens — $260 $285 +25 +16.2% $245.35
2026-07-27 UBS — $288 $308 +20 +25.4% $245.61
2026-07-27 Piper Sandler — Initiated $308 — +24.8% $246.84
2026-07-27 Morgan Stanley — $254 $274 +20 +12.3% $243.89
2026-07-27 Raymond James Sarah James $245 $270 +25 +10.5% $244.44
2026-07-27 RBC Capital — $277 $283 +6 +21.4% $233.20
2026-07-24 Barclays — $238 $271 +33 +36.2% $199.02
2026-07-20 Guggenheim — $283 $242 -41 +24.2% $194.91
2026-07-13 Wells Fargo Stephen Baxter $265 $231 -34 +13.1% $204.25
2026-05-05 Robert W. Baird — $153 $210 +57 +13.3% $185.35
2026-05-05 Barclays Andrew Mok $257 $238 -19 +28.4% $185.35
2026-05-04 Stephens Scott Fidel $122 $260 +138 +41.9% $183.27
2026-05-01 Morgan Stanley — $260 $254 -6 +38.1% $183.95
2026-03-12 Guggenheim Jason Cassorla $271 $283 +12 +20.6% $234.58
2026-02-17 Truist Financial — $240 $270 +30 +16.3% $232.06
2026-02-16 Wells Fargo Stephen Baxter $229 $265 +36 +14.7% $231.10
2026-02-13 Guggenheim — $257 $271 +14 +16.7% $232.26
2026-02-13 Barclays Andrew Mok $240 $257 +17 +10.7% $232.26
2026-02-12 UBS — $260 $288 +28 +23.3% $233.50
2026-02-12 Morgan Stanley — $247 $260 +13 +13.7% $228.75
2026-02-12 RBC Capital — $253 $277 +24 +22.4% $226.35
2026-02-12 KeyBanc Matthew Gillmor $225 $250 +25 +10.4% $226.35
2026-02-03 RBC Capital Ben Hendrix $252 $253 +1 +29.8% $194.98
2026-01-07 Wells Fargo — $238 $229 -9 +10.0% $208.24
2025-12-18 Morgan Stanley Craig Hettenbach $232 $247 +15 +26.7% $195.02
2025-12-02 Guggenheim — $238 $257 +19 +19.5% $215.13
2025-11-21 Barclays Andrew Mok $229 $240 +11 +28.6% $186.68
2025-11-03 Truist Financial — $225 $240 +15 +19.6% $200.74
2025-10-30 RBC Capital — $136 $252 +116 +18.6% $212.48
2025-10-29 Raymond James Sarah James $135 $245 +110 +17.4% $208.72
2025-10-29 UBS — $47 $260 +213 +24.6% $208.72
2025-10-29 Morgan Stanley — $165 $232 +67 +11.7% $207.78
2025-10-29 Guggenheim — Initiated $238 — +16.3% $204.62
2025-10-17 Mizuho Securities Ann Hynes $170 $225 +55 +13.0% $199.13
2025-10-14 Truist Financial David MacDonald $205 $225 +20 +16.8% $192.65
2025-10-14 Goldman Sachs Scott Fidel $140 $224 +84 +17.9% $190.00
2025-10-08 KeyBanc Matthew Gillmor $185 $225 +40 +9.8% $204.83
2025-10-07 Wells Fargo Stephen Baxter $59 $238 +179 +19.1% $199.76
2025-09-18 Barclays — $156 $229 +73 +23.0% $186.12
2025-07-16 Truist Financial David MacDonald $170 $205 +35 +19.0% $172.27
2025-03-26 Morgan Stanley — Initiated $165 — +24.0% $133.04
2025-01-07 KeyBanc Matthew Gillmor Initiated $185 — +43.6% $128.80

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

A
Oct 27, 2026
DCF
5
ROE
5
ROA
5
D/E
1
P/E
4
P/B
2
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. THC receives an overall rating of A. Strongest factors: DCF (5/5), ROE (5/5), ROA (5/5), P/E (4/5). Areas of concern: D/E (1/5), P/B (2/5).
Rating Change History
DateFromTo
2026-10-26 A- A
2026-05-04 A+ A-
2026-04-30 C A+
2026-04-30 A- C
2026-04-01 B+ A-
2026-03-30 A- B+
2026-02-27 B+ A-

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 63 Grade B
Profitability
56
Balance Sheet
36
Earnings Quality
76
Growth
66
Value
67
Momentum
88
Safety
50
Cash Flow
69
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. THC scores highest in Momentum (88/100) and lowest in Balance Sheet (36/100). A grade of B indicates above-average fundamentals with room for improvement in select areas.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
1.95
Grey Zone
Piotroski F-Score
7/9
✓ ✓ ✓ ✓ ✓ ✗ ✓ ✗ ✓
Beneish M-Score
-1.11
Possible Manipulator
Ohlson O-Score
-7.49
Bankruptcy prob: 0.1%
Low Risk
Credit Rating
BBB
Score: 59.0/100
Trend: Improving
Earnings Quality
75/100
OCF/NI: 1.79x
Accruals: -6.0%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. THC scores 1.95, placing it in the Grey Zone (safe > 2.99, distress < 1.81). Financial distress is possible and warrants monitoring. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. THC scores 7/9, signaling strong financial health across all three dimensions. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. THC's score of -1.11 exceeds the −1.78 red flag threshold — this does not confirm manipulation but indicates the earnings profile resembles past manipulators statistically. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. THC's implied 0.1% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. THC receives an estimated rating of BBB (score: 59.0/100), with a improving trend. The Earnings Quality score measures how well reported earnings are backed by real cash. It evaluates the operating cash flow to net income ratio (OCF/NI ≥ 1.0 means every dollar of earnings is cash-backed) and the accruals ratio (the gap between earnings and cash flow relative to assets — lower is better). THC's score of 75/100 is high — cash flows strongly support reported earnings.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
10.02x
PEG
0.15x
P/S
0.97x
P/B
4.69x
P/FCF
5.20x
P/OCF
3.91x
EV/EBITDA
5.30x
EV/Revenue
1.23x
EV/EBIT
6.43x
EV/FCF
8.86x
Earnings Yield
14.27%
FCF Yield
19.24%
Shareholder Yield
10.54%
Graham Number
$182.52
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. At 10.0x earnings, THC trades at a reasonable valuation. An earnings yield of 14.3% exceeds typical risk-free rates, suggesting equities are being compensated for risk. Graham's intrinsic value formula yields $182.52 per share, 47% below the current price.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
0.580
NI / EBT
×
Interest Burden
0.928
EBT / EBIT
×
EBIT Margin
0.191
EBIT / Rev
×
Asset Turnover
0.735
Rev / Assets
×
Equity Multiplier
7.063
Assets / Equity
=
ROE
53.3%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. THC's ROE of 53.3% is driven by financial leverage (equity multiplier: 7.06x). Note: high leverage means ROE is amplified by debt rather than operational performance. A tax burden ratio of 0.58 suggests the company retains less than 60% of pre-tax earnings after taxes.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate
15.00%
Fair P/E
38.50x
Intrinsic Value
$1027.57
Price/Value
0.18x
Margin of Safety
81.79%
Premium
-81.79%
Assessment
Undervalued
Graham's classic formula uses analyst-projected growth to estimate a fair P/E (8.5 + 2g). Our adjusted version replaces that projection with THC's realized 15.0% 3-year EPS CAGR, capped at 15% — demonstrated performance rather than forecasts, held to a rate companies have historically sustained. THC actually compounded EPS at 77.6% over three years; the model uses 15%, the highest rate it will extrapolate — of 4,457 company-quarters that grew faster than 200%, none sustained it over the following seven years. At an intrinsic value of $1027.57, THC appears undervalued with a 82% margin of safety. The adjusted fair P/E of 38.5x compares to the current market P/E of 10.0x.

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$268.94
Median 1Y
$331.25
5th Pctile
$134.72
95th Pctile
$819.83
Ann. Volatility
55.3%
Analyst Target
$287.88
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Saum Sutaria
Chairman and Chief Executive Officer
$1,500,000 $31,677,365 $43,108,969
Tom Arnst EVP,
Chief Administrative Officer, General Counsel and Corporate Secretary
$650,000 $3,740,183 $10,049,603
Lisa Foo EVP
and Chief Operating Officer
$650,000 $3,382,855 $9,542,814
Sun Park EVP
and Chief Financial Officer
$700,000 $2,722,562 $7,374,108
Paola Arbour EVP
and Chief Information Officer
$550,000 $1,393,533 $4,096,174

CEO Pay Ratio

Insufficient data for pay ratio.

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
100,000
+2.0% YoY
Revenue / Employee
$213,100
Rev: $21,310,000,000
Profit / Employee
$14,070
NI: $1,407,000,000
SGA / Employee
—
Avg labor cost proxy

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
ROE 6.2% 1.7% 1.6% 1.3% 57.0% 37.9% 36.2% 41.1% 34.8% 44.4% 1.1% 1.1% 1.2% 1.1% 38.1% 41.1% 34.5% 33.5% 37.9% 53.3% 53.31%
ROA 4.1% 3.3% 3.6% 3.3% 2.1% 1.5% 1.5% 1.9% 1.7% 2.2% 9.4% 9.8% 11.0% 11.2% 5.0% 5.1% 4.6% 4.8% 5.6% 7.5% 7.55%
ROIC 19.1% 15.7% 15.9% 15.0% 12.5% 11.3% 11.1% 11.8% 11.9% 13.2% 29.1% 30.9% 35.9% 29.8% 20.2% 20.7% 20.2% 20.5% 19.3% 19.1% 19.12%
ROCE 14.5% 12.5% 13.2% 12.8% 10.7% 9.9% 9.8% 10.2% 10.0% 10.7% 22.2% 22.8% 25.0% 24.7% 15.1% 15.6% 14.5% 14.4% 15.9% 16.6% 16.59%
Gross Margin 37.9% 37.6% 37.4% 36.6% 36.5% 36.5% 37.2% 37.5% 37.5% 39.6% 39.4% 39.7% 39.5% 40.3% 42.0% 82.3% 58.3% 15.7% 16.4% 18.2% 18.19%
Operating Margin 20.7% 15.5% 13.7% 11.9% 12.4% 10.7% 12.0% 11.9% 11.2% 13.7% 61.2% 14.9% 21.3% 16.2% 18.1% 15.6% 16.8% 15.7% 16.4% 18.2% 18.19%
Net Margin 9.2% 5.1% 3.0% 0.8% 2.7% 2.0% 2.8% 2.4% 2.0% 4.5% 40.1% 5.1% 9.2% 6.3% 7.8% 5.5% 6.5% 6.7% 13.1% 14.7% 14.68%
EBITDA Margin 24.7% 19.6% 17.0% 15.2% 16.9% 15.1% 16.3% 16.0% 15.7% 17.9% 65.4% 19.6% 26.0% 20.7% 22.5% 20.0% 21.5% 20.2% 29.2% 22.0% 22.01%
FCF Margin 5.8% 4.7% 2.9% 2.2% 1.3% 1.7% 2.4% 4.8% 5.6% 7.9% 8.4% 9.0% 11.4% 5.4% 6.9% 7.6% 7.2% 11.9% 15.6% 13.9% 13.86%
OCF Margin 8.5% 8.0% 6.5% 5.9% 5.4% 5.6% 6.7% 9.0% 9.8% 11.6% 12.0% 12.7% 15.3% 9.9% 11.1% 11.9% 11.9% 16.6% 20.3% 18.4% 18.41%
ROE 3Y Avg snapshot only 55.66%
ROE 5Y Avg snapshot only 56.94%
ROA 3Y Avg snapshot only 7.30%
ROIC 3Y Avg snapshot only 13.69%
ROIC Economic snapshot only 17.22%
Cash ROA snapshot only 13.09%
Cash ROIC snapshot only 25.51%
CROIC snapshot only 19.21%
NOPAT Margin snapshot only 13.79%
Pretax Margin snapshot only 17.72%
R&D / Revenue snapshot only 0.00%
SGA / Revenue snapshot only 30.30%
SBC / Revenue snapshot only 0.40%
Valuation
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
P/E Ratio 6.70 9.73 10.06 6.53 10.16 12.63 15.21 17.09 14.67 12.88 4.04 4.75 5.14 3.78 8.78 10.89 13.29 12.42 9.71 7.01 10.020
P/S Ratio 0.37 0.46 0.50 0.30 0.30 0.27 0.32 0.43 0.34 0.38 0.51 0.63 0.77 0.59 0.62 0.78 0.86 0.82 0.77 0.72 0.966
P/B Ratio 10.01 8.65 9.12 5.26 4.59 4.54 5.11 6.35 4.70 4.90 3.06 3.77 4.19 2.90 3.06 4.31 4.48 4.14 3.43 3.37 4.693
P/FCF 6.36 9.77 16.89 13.81 23.33 16.17 13.63 8.87 6.05 4.85 6.06 6.96 6.71 10.85 8.99 10.34 11.98 6.91 4.94 5.20 5.196
P/OCF 4.36 5.67 7.63 5.03 5.56 4.79 4.83 4.78 3.49 3.32 4.21 4.92 5.02 5.91 5.62 6.55 7.26 4.94 3.79 3.91 3.912
EV/EBITDA 4.93 6.05 6.16 5.29 5.98 6.31 6.68 7.09 6.56 6.39 3.45 3.68 3.65 3.40 5.04 5.79 6.38 6.19 5.49 5.30 5.296
EV/Revenue 0.98 1.14 1.19 1.02 1.03 1.01 1.06 1.14 1.04 1.05 1.00 1.10 1.18 1.13 1.12 1.29 1.35 1.30 1.25 1.23 1.228
EV/EBIT 6.40 7.89 7.93 6.84 8.00 8.69 9.24 9.67 9.03 8.60 4.02 4.27 4.17 3.85 6.14 7.03 7.85 7.67 6.71 6.43 6.431
EV/FCF 16.77 24.37 40.48 46.95 80.47 60.47 44.62 23.56 18.34 13.34 12.02 12.27 10.38 20.98 16.14 17.09 18.78 10.97 7.99 8.86 8.861
Earnings Yield 14.9% 10.3% 9.9% 15.3% 9.8% 7.9% 6.6% 5.9% 6.8% 7.8% 24.8% 21.0% 19.5% 26.4% 11.4% 9.2% 7.5% 8.1% 10.3% 14.3% 14.27%
FCF Yield 15.7% 10.2% 5.9% 7.2% 4.3% 6.2% 7.3% 11.3% 16.5% 20.6% 16.5% 14.4% 14.9% 9.2% 11.1% 9.7% 8.3% 14.5% 20.3% 19.2% 19.24%
PEG Ratio snapshot only 0.152
EV/OCF snapshot only 6.671
EV/Gross Profit snapshot only 4.571
Acquirers Multiple snapshot only 7.311
Shareholder Yield snapshot only 10.54%
Graham Number snapshot only $182.52
Leverage & Solvency
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Current Ratio 1.28 1.38 1.31 1.39 1.40 1.34 1.39 1.44 1.43 1.51 1.44 1.45 1.58 1.78 1.78 1.71 1.71 1.76 1.36 1.41 1.406
Quick Ratio 1.21 1.31 1.23 1.30 1.31 1.25 1.29 1.35 1.34 1.42 1.37 1.38 1.52 1.70 1.70 1.63 1.64 1.68 1.30 1.35 1.345
Debt/Equity 19.58 15.22 14.06 13.87 12.22 13.20 12.23 11.20 10.27 9.33 3.73 3.70 3.36 3.43 3.15 3.51 3.29 3.12 2.74 2.84 2.844
Net Debt/Equity 16.40 12.92 12.73 12.62 11.24 12.45 11.61 10.51 9.55 8.57 3.01 2.88 2.29 2.71 2.43 2.81 2.54 2.44 2.13 2.38 2.378
Debt/Assets 0.55 0.57 0.56 0.57 0.56 0.56 0.56 0.55 0.55 0.53 0.45 0.44 0.44 0.50 0.45 0.46 0.45 0.44 0.42 0.43 0.432
Debt/EBITDA 3.66 4.27 3.97 4.11 4.61 4.90 4.89 4.71 4.73 4.43 2.12 2.05 1.89 2.08 2.89 2.85 2.98 2.94 2.71 2.62 2.619
Net Debt/EBITDA 3.06 3.62 3.59 3.74 4.24 4.62 4.64 4.42 4.40 4.07 1.71 1.59 1.29 1.64 2.23 2.29 2.31 2.29 2.10 2.19 2.190
Interest Coverage 3.16 3.05 3.20 3.17 2.74 2.51 2.52 2.64 2.59 2.79 5.81 6.18 7.01 7.35 4.61 4.66 4.39 4.41 4.85 5.08 5.079
Equity Multiplier 35.89 26.83 25.24 24.49 21.92 23.78 21.95 20.22 18.85 17.61 8.37 8.42 7.66 6.94 6.99 7.66 7.33 7.03 6.48 6.59 6.586
Cash Ratio snapshot only 0.390
Debt Service Coverage snapshot only 6.168
Cash to Debt snapshot only 0.164
FCF to Debt snapshot only 0.228
Defensive Interval snapshot only 794.2 days
Efficiency & Turnover
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Asset Turnover 0.75 0.71 0.73 0.72 0.72 0.70 0.72 0.74 0.74 0.74 0.75 0.74 0.74 0.72 0.71 0.71 0.71 0.73 0.71 0.73 0.735
Inventory Turnover 33.76 32.48 32.09 31.89 31.14 30.74 30.85 31.72 31.38 31.23 32.03 32.42 32.97 32.91 33.11 28.02 26.18 31.19 35.75 47.20 47.195
Receivables Turnover 6.25 5.85 5.85 5.91 6.13 5.67 5.76 5.95 6.35 5.99 6.00 6.27 6.53 6.40 6.07 7.06 7.46 7.58 7.45 8.49 8.486
Payables Turnover 11.52 9.74 10.99 11.05 10.25 8.65 10.67 10.77 10.37 8.75 10.16 10.13 10.28 9.22 9.19 7.67 7.01 8.16 9.21 11.68 11.682
DSO 58 62 62 62 60 64 63 61 57 61 61 58 56 57 60 52 49 48 49 43 43.0 days
DIO 11 11 11 11 12 12 12 12 12 12 11 11 11 11 11 13 14 12 10 8 7.7 days
DPO 32 37 33 33 36 42 34 34 35 42 36 36 36 40 40 48 52 45 40 31 31.2 days
Cash Conversion Cycle 38 36 41 40 36 34 41 39 34 31 36 33 31 29 31 17 11 15 20 20 19.5 days
Fixed Asset Turnover snapshot only 3.485
Operating Cycle snapshot only 50.7 days
Cash Velocity snapshot only 10.052
Capital Intensity snapshot only 1.406
Growth (YoY)
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue 11.5% 10.5% 8.6% -0.4% -2.6% -1.6% 0.0% 4.0% 5.9% 7.2% 7.4% 5.1% 4.0% 0.6% -1.8% -1.1% -0.6% 3.1% 4.6% 5.4% 5.43%
Net Income 60.9% 1.3% 1.4% 1.0% -48.3% -55.0% -56.7% -43.0% -15.9% 48.7% 5.3% 4.5% 5.7% 4.2% -44.4% -46.1% -56.7% -56.0% 17.0% 51.0% 51.01%
EPS 59.0% 1.3% 1.3% 1.0% -48.8% -54.0% -54.3% -40.9% -11.6% 51.8% 5.7% 4.9% 6.2% 4.7% -41.2% -42.2% -52.8% -52.0% 27.0% 65.1% 65.09%
FCF -61.2% -68.3% -82.9% -68.7% -78.6% -64.7% -18.9% 1.3% 3.7% 4.1% 2.8% 95.7% 1.1% -31.2% -18.5% -16.9% -37.2% 1.3% 1.4% 93.4% 93.41%
EBITDA 76.2% 44.8% 37.1% 29.7% -15.4% -16.1% -17.6% -13.0% -2.8% 10.2% 97.1% 96.2% 1.1% 1.0% -25.0% -26.3% -35.1% -34.9% 7.0% 9.6% 9.60%
Op. Income 99.6% 44.3% 37.4% 29.1% -16.2% -18.7% -23.7% -21.1% -9.3% 7.6% 1.3% 1.3% 1.5% 1.4% -30.4% -31.3% -40.8% -40.8% -4.2% -0.3% -0.33%
OCF Growth snapshot only 62.88%
Asset Growth snapshot only 6.89%
Equity Growth snapshot only 24.25%
Debt Growth snapshot only 0.55%
Shares Change snapshot only -8.53%
Growth (CAGR)
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue 3Y 1.5% 2.1% 2.3% 1.7% 1.3% 1.2% 1.8% 4.3% 4.8% 5.2% 5.3% 2.9% 2.4% 2.0% 1.8% 2.6% 3.1% 3.6% 3.3% 3.1% 3.12%
Revenue 5Y -0.2% -0.1% 0.1% -0.2% -0.0% -0.0% 0.4% 1.2% 1.5% 2.3% 2.8% 2.8% 2.8% 2.3% 2.1% 3.4% 3.5% 3.9% 3.7% 2.6% 2.58%
EPS 3Y — 98.1% — — — — — — — 16.4% 91.1% 91.3% 48.3% 58.4% 21.5% 26.1% 44.4% 60.6% 70.7% 77.6% 77.63%
EPS 5Y — — — — — — — — — 40.3% — — — — — — — 33.9% 39.1% 46.2% 46.19%
Net Income 3Y — 1.0% — — — — — — — 15.3% 86.6% 85.2% 42.6% 51.8% 15.0% 19.2% 34.4% 50.7% 60.2% 65.0% 64.99%
Net Income 5Y — — — — — — — — — 40.7% — — — — — — — 28.7% 33.4% 38.9% 38.86%
EBITDA 3Y 15.3% 14.5% 18.2% 17.1% 16.2% 10.2% 10.6% 10.8% 13.1% 10.2% 30.6% 30.3% 20.7% 23.4% 6.8% 7.9% 10.5% 13.4% 16.5% 16.6% 16.56%
EBITDA 5Y 12.9% 12.0% 13.4% 12.7% 15.3% 11.3% 8.7% 8.4% 4.7% 6.7% 21.8% 22.4% 26.7% 24.6% 14.8% 14.5% 15.0% 12.1% 12.3% 12.3% 12.31%
Gross Profit 3Y 2.2% 2.9% 3.2% 2.4% 2.0% 1.7% 2.5% 6.2% 6.9% 7.8% 7.7% 4.9% 4.3% 4.1% 4.5% 14.0% 18.3% 14.2% 8.7% -7.3% -7.27%
Gross Profit 5Y 0.4% 0.3% 0.8% 0.8% 1.1% 0.7% 0.9% 1.6% 1.8% 3.2% 4.0% 4.2% 4.5% 4.1% 4.6% 11.5% 13.7% 11.0% 7.3% -3.7% -3.71%
Op. Income 3Y 20.7% 20.4% 25.7% 25.4% 19.7% 14.9% 15.6% 14.6% 14.9% 8.1% 33.5% 32.5% 24.5% 27.5% 6.4% 7.4% 10.9% 14.7% 14.8% 16.1% 16.14%
Op. Income 5Y 18.8% 18.3% 21.1% 20.1% 23.1% 16.0% 10.9% 9.9% 6.0% 8.8% 28.0% 28.9% 31.6% 31.1% 19.5% 18.8% 17.9% 12.1% 9.7% 9.8% 9.79%
FCF 3Y 19.2% 28.2% 26.7% 28.1% -2.0% -17.1% -12.6% -29.0% -27.0% -17.3% -19.4% 12.4% 28.2% 7.0% 35.6% 55.7% 83.5% 99.0% 93.5% 46.5% 46.52%
FCF 5Y 49.5% — — — — -8.2% -0.6% 8.7% 11.1% 30.3% 44.2% 57.0% 56.1% 14.7% 15.5% -10.3% -12.5% -2.5% 0.1% 18.0% 17.97%
OCF 3Y 8.7% 14.3% 10.1% 8.8% 1.9% -4.2% -1.2% -18.6% -17.3% -11.3% -13.0% 13.5% 24.6% 9.3% 21.7% 29.5% 34.5% 48.4% 49.6% 31.1% 31.07%
OCF 5Y 9.7% 23.0% 16.1% 24.7% 19.6% -2.0% 3.0% 7.2% 8.8% 17.7% 21.6% 24.7% 27.2% 10.7% 11.0% -5.7% -6.6% 0.8% 2.8% 17.2% 17.17%
Assets 3Y 5.2% 7.2% 4.8% 4.7% 5.0% 5.2% 4.3% 1.1% 1.8% 1.5% 2.9% 3.3% 4.3% 1.6% 3.1% 2.5% 2.8% 3.0% 4.9% 4.1% 4.15%
Assets 5Y 1.1% 2.2% 1.7% 1.8% 3.1% 3.0% 3.1% 4.0% 4.4% 4.8% 4.5% 4.7% 4.7% 4.4% 4.2% 1.8% 2.4% 1.8% 3.3% 2.9% 2.92%
Equity 3Y — — — — — — — — — 2.9% 2.0% 1.4% 74.5% 59.5% 58.2% 51.1% 48.1% 54.6% 57.5% 51.4% 51.37%
Book Value 3Y — — — — — — — — — 2.9% 2.1% 1.4% 81.5% 66.4% 67.1% 59.9% 59.1% 64.7% 67.8% 63.0% 62.97%
Dividend 3Y — — — — — — — — — — — — — — — — — — — — —
Growth Quality
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue Stability 0.14 0.08 0.02 0.00 0.02 0.01 0.09 0.36 0.40 0.61 0.76 0.91 0.85 0.86 0.85 0.94 0.94 0.96 0.91 0.91 0.907
Earnings Stability 0.57 0.66 0.74 0.79 0.71 0.67 0.71 0.79 0.46 0.45 0.65 0.67 0.61 0.60 0.58 0.58 0.39 0.37 0.41 0.54 0.538
Margin Stability 0.98 0.98 0.98 0.97 0.97 0.98 0.98 0.97 0.97 0.97 0.97 0.97 0.97 0.96 0.95 0.84 0.79 0.86 0.93 0.77 0.772
Rev. Growth Consistency 0.50 0.50 0.50 0.00 0.00 0.00 1.00 0.50 0.50 0.50 1.00 1.00 1.00 1.00 0.00 0.00 0.00 1.00 0.50 0.50 0.500
Earn. Growth Consistency 1.00 1.00 1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 1.00 0.00 0.00 0.00 0.00 0.50 0.50 0.500
FCF Positive Streak 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Earnings Persistence 0.20 0.50 0.50 0.50 0.50 0.50 0.50 0.83 0.94 0.81 0.50 0.50 0.50 0.50 0.82 0.82 0.50 0.50 0.93 0.50 0.500
Earnings Smoothness — 0.22 0.19 0.33 0.36 0.24 0.21 0.45 0.83 0.61 0.00 0.00 0.00 0.00 0.43 0.40 0.21 0.22 0.84 0.59 0.594
ROE Trend — — — — — -7.21 -1.76 -0.86 -0.65 -0.24 0.14 0.20 0.43 0.40 -0.20 -0.19 -0.23 -0.24 -0.20 -0.11 -0.113
Gross Margin Trend 0.02 0.02 0.01 0.01 0.01 0.00 0.00 -0.00 -0.00 0.01 0.01 0.02 0.02 0.02 0.03 0.13 0.18 0.10 0.03 -0.18 -0.183
FCF Margin Trend -0.03 -0.05 -0.08 -0.09 -0.10 -0.09 -0.08 0.00 0.02 0.05 0.06 0.05 0.08 0.01 0.02 0.01 -0.01 0.05 0.08 0.06 0.056
Sustainable Growth Rate 6.2% 1.7% 1.6% 1.3% 57.0% 37.9% 36.2% 41.1% 34.8% 44.4% 1.1% 1.1% 1.2% 1.1% 38.1% 41.1% 34.5% 33.5% 37.9% 53.3% 53.31%
Internal Growth Rate 4.3% 3.5% 3.7% 3.4% 2.2% 1.5% 1.6% 1.9% 1.7% 2.3% 10.3% 10.8% 12.3% 12.6% 5.3% 5.4% 4.8% 5.0% 6.0% 8.2% 8.16%
Cash Flow Quality
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
OCF/Net Income 1.54 1.72 1.32 1.30 1.83 2.64 3.15 3.57 4.20 3.89 0.96 0.97 1.02 0.64 1.56 1.66 1.83 2.52 2.56 1.79 1.792
FCF/OCF 0.69 0.58 0.45 0.36 0.24 0.30 0.35 0.54 0.58 0.68 0.69 0.71 0.75 0.55 0.62 0.63 0.61 0.71 0.77 0.75 0.753
FCF/Net Income snapshot only 1.349
OCF/EBITDA snapshot only 0.794
CapEx/Revenue 2.7% 3.4% 3.6% 3.8% 4.1% 4.0% 4.3% 4.1% 4.1% 3.7% 3.7% 3.7% 3.9% 4.5% 4.2% 4.4% 4.7% 4.7% 4.7% 4.5% 4.55%
CapEx/Depreciation snapshot only 1.111
Accruals Ratio -0.02 -0.02 -0.01 -0.01 -0.02 -0.02 -0.03 -0.05 -0.05 -0.06 0.00 0.00 -0.00 0.04 -0.03 -0.03 -0.04 -0.07 -0.09 -0.06 -0.060
Sloan Accruals snapshot only -0.056
Cash Flow Adequacy snapshot only 4.047
Earnings Quality Score snapshot only 0.750
Dividends & Buybacks
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
FCF Payout Ratio 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Total Payout Ratio 0.0% 0.0% 0.0% 0.0% 0.0% 60.8% 72.5% 68.1% 72.5% 32.7% 16.3% 23.9% 25.0% 0.0% 4.8% 36.9% 38.1% 98.8% 79.9% 73.9% 73.85%
Div. Increase Streak — — — — — — — — — — — — — — — — — — — — —
Chowder Number — — — — — — — — — — — — — — — — — — — — —
Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 4.8% 4.8% 4.0% 4.9% 2.5% 4.0% 5.0% 4.9% 0.0% 0.5% 3.4% 2.9% 8.0% 8.2% 10.5% 10.54%
Net Buyback Yield -0.3% 0.0% -0.1% -0.2% -0.2% 4.8% 4.8% 4.0% 4.9% 2.5% 4.0% 5.0% 4.9% 0.0% 0.5% 3.4% 2.9% 8.0% 8.2% 10.5% 10.54%
Total Shareholder Return -0.3% 0.0% -0.1% -0.2% -0.2% 4.8% 4.8% 4.0% 4.9% 2.5% 4.0% 5.0% 4.9% 0.0% 0.5% 3.4% 2.9% 8.0% 8.2% 10.5% 10.54%
DuPont Factors
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Tax Burden (NI/EBT) 0.53 0.48 0.48 0.45 0.36 0.31 0.31 0.34 0.33 0.38 0.61 0.61 0.61 0.61 0.50 0.50 0.49 0.50 0.54 0.58 0.580
Interest Burden (EBT/EBIT) 0.68 0.67 0.69 0.68 0.63 0.60 0.60 0.62 0.61 0.64 0.83 0.84 0.86 0.86 0.78 0.79 0.77 0.77 0.79 0.93 0.928
EBIT Margin 0.15 0.14 0.15 0.15 0.13 0.12 0.11 0.12 0.11 0.12 0.25 0.26 0.28 0.29 0.18 0.18 0.17 0.17 0.19 0.19 0.191
Asset Turnover 0.75 0.71 0.73 0.72 0.72 0.70 0.72 0.74 0.74 0.74 0.75 0.74 0.74 0.72 0.71 0.71 0.71 0.73 0.71 0.73 0.735
Equity Multiplier 149.71 51.79 45.13 39.46 27.08 25.22 23.47 22.13 20.25 20.17 11.94 11.71 10.75 9.91 7.62 8.02 7.49 6.99 6.72 7.06 7.063
Per Share
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
EPS (Diluted TTM) $9.92 $8.39 $8.54 $8.06 $5.08 $3.86 $3.91 $4.76 $4.49 $5.87 $26.03 $27.99 $32.34 $33.37 $15.31 $16.17 $15.28 $16.00 $19.44 $26.69 $26.69
Book Value/Share $6.64 $9.44 $9.43 $10.00 $11.24 $10.74 $11.63 $12.82 $14.02 $15.44 $34.32 $35.30 $39.67 $43.50 $44.00 $40.84 $45.30 $48.00 $54.96 $55.48 $104.16
Tangible Book/Share $-86.61 $-89.36 $-87.33 $-90.61 $-92.69 $-97.82 $-98.65 $-99.38 $-99.12 $-96.64 $-84.63 $-88.75 $-84.09 $-82.57 $-84.25 $-93.23 $-95.84 $-94.70 $-90.06 $-95.99 $-95.99
Revenue/Share $179.70 $178.94 $173.62 $175.94 $173.27 $180.26 $183.48 $189.87 $193.05 $197.26 $207.71 $212.47 $216.98 $215.53 $215.96 $225.38 $235.36 $242.39 $244.93 $259.78 $261.15
FCF/Share $10.45 $8.36 $5.09 $3.81 $2.21 $3.02 $4.36 $9.17 $10.90 $15.58 $17.35 $19.11 $24.76 $11.64 $14.97 $17.03 $16.95 $28.78 $38.23 $36.00 $36.19
OCF/Share $15.24 $14.40 $11.27 $10.45 $9.27 $10.18 $12.30 $17.02 $18.87 $22.79 $24.96 $27.02 $33.13 $21.35 $23.95 $26.85 $27.97 $40.27 $49.84 $47.82 $48.07
Cash/Share $21.07 $21.71 $12.54 $12.42 $10.99 $8.07 $7.23 $8.91 $10.09 $11.79 $24.66 $29.26 $42.36 $31.49 $31.56 $28.60 $33.57 $32.79 $33.87 $25.84 $25.98
EBITDA/Share $35.56 $33.67 $33.41 $33.76 $29.78 $28.91 $29.10 $30.48 $30.44 $32.52 $60.44 $63.65 $70.39 $71.88 $47.96 $50.28 $49.86 $51.00 $55.65 $60.24 $60.24
Debt/Share $129.95 $143.69 $132.57 $138.59 $137.35 $141.76 $142.28 $143.62 $144.05 $144.02 $128.02 $130.74 $133.17 $149.42 $138.60 $143.53 $148.82 $149.81 $150.79 $157.78 $157.78
Net Debt/Share $108.88 $121.98 $120.03 $126.17 $126.36 $133.70 $135.06 $134.70 $133.95 $132.23 $103.36 $101.49 $90.81 $117.94 $107.04 $114.94 $115.25 $117.02 $116.92 $131.94 $131.94
Academic Models
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Altman Z-Score — — — — — — — — — — — — — — — — — — — — 1.948
Altman Z-Prime snapshot only 2.778
Piotroski F-Score 7 6 7 6 4 5 6 8 8 9 8 8 9 7 6 6 6 6 7 7 7
Beneish M-Score -2.50 -2.55 -2.45 -2.42 -2.57 -2.93 -2.62 -2.68 -2.62 -2.81 -2.41 -2.49 -2.61 -2.40 -2.75 -6.07 -5.86 -1.91 -5.80 -1.11 -1.112
Ohlson O-Score snapshot only -7.493
Net-Net WC snapshot only $-168.51
EVA snapshot only $1435335575.68
Credit
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Credit Rating snapshot only BBB
Credit Score 38.66 37.15 37.88 36.71 28.17 28.76 28.30 35.95 35.48 39.45 56.19 55.71 61.73 58.91 48.64 53.30 53.74 55.45 54.62 59.01 59.010
Credit Grade snapshot only 9
Credit Trend snapshot only 5.709
Implied Spread (bps) snapshot only 275.000
Industry Credit Rank snapshot only 52
Sector Credit Rank snapshot only 52

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms